Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC lowered its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 54.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 421,384 shares of the company's stock after selling 503,011 shares during the quarter. Clearbridge Investments LLC owned 0.45% of Scholar Rock worth $18,212,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in SRRK. GAMMA Investing LLC boosted its stake in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after acquiring an additional 269 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Scholar Rock by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after buying an additional 379 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after buying an additional 620 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after buying an additional 766 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after buying an additional 1,031 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Scholar Rock

In other news, insider Jing L. Marantz sold 5,655 shares of Scholar Rock stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the sale, the insider now owns 67,200 shares of the company's stock, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jay T. Backstrom sold 22,308 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $986,013.60. Following the completion of the transaction, the chief executive officer now owns 330,363 shares of the company's stock, valued at $14,602,044.60. The trade was a 6.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 299,772 shares of company stock worth $11,245,798 in the last ninety days. 19.20% of the stock is owned by insiders.

Scholar Rock Trading Down 3.2 %

Shares of SRRK traded down $0.86 during mid-day trading on Monday, reaching $26.04. The stock had a trading volume of 1,686,120 shares, compared to its average volume of 1,195,882. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -11.08 and a beta of 0.56. The business's fifty day moving average is $35.98 and its 200 day moving average is $34.14. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.